Influenza as an issue on the agenda of policy makers and government representatives - What can we do? What do we need?

被引:4
|
作者
Esveld, Maja
机构
关键词
D O I
10.1016/j.vaccine.2006.06.068
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Influenza vaccinations and antiviral drugs are the foundation of epidemic and pandemic preparedness, but only close collaboration between public health authorities and industry can achieve the necessary production levels and ensure the smooth distribution necessary to protect European citizens from this public health scourge. To focus the minds of all public health stakeholders, ESWI has translated these simple facts into clear achievable goals: it recommends that EU governments vaccinate one-third of their populations by 20 10 and stockpile antiviral drugs for 20% of their citizens while promoting public-private partnerships. The scientific justification behind this objective is easily understood namely that while the annual flu shot protects against three viral strains, the pandemic vaccine will focus on only the one highly lethal virus. As a result if countries succeed in meeting the target to vaccine one-third of the EU-25 population with a trivalent vaccine, sufficient monovalent pandemic vaccine could be produced to vaccinate almost the entire EU-25 population at least once. Achieving these objectives would go far to containing the pandemic and ensuring necessary treatment to avoid needless deaths and social and economic disruption. It would also signal that influenza preparedness had become part of the European mindset. Relying on the technique of force-field analysis organised by professional facilitators the session asked government representatives and policy makers to identify existing factors that either provide support for the objectives or hinder progress.
引用
收藏
页码:6793 / 6795
页数:3
相关论文
共 50 条
  • [32] The AI Moonshot: What We Need and What We Do Not
    Rodriguez, Jose E.
    Lussier, Yves
    ANNALS OF FAMILY MEDICINE, 2025, 23 (01)
  • [33] Neurocognitive enhancement: what can we do and what should we do?
    Farah, MJ
    Illes, J
    Cook-Deegan, R
    Gardner, H
    Kandel, E
    King, P
    Parens, E
    Sahakian, B
    Wolpe, PR
    NATURE REVIEWS NEUROSCIENCE, 2004, 5 (05) : 421 - 425
  • [34] Logistic Regression: Why We Cannot Do What We Think We Can Do, and What We Can Do About It
    Mood, Carina
    EUROPEAN SOCIOLOGICAL REVIEW, 2010, 26 (01) : 67 - 82
  • [35] Violent Attacks: What Do We Know? What Can We Do?
    Ganellen, Ronald J.
    JOURNAL OF PERSONALITY ASSESSMENT, 2018, 100 (05) : 449 - 450
  • [36] Polarization: What Do We Know and What Can We Do About It?
    Casal Bertoa, Fernando
    Rama, Jose
    FRONTIERS IN POLITICAL SCIENCE, 2021, 3
  • [37] Neurocognitive enhancement: what can we do and what should we do?
    Martha J. Farah
    Judy Illes
    Robert Cook-Deegan
    Howard Gardner
    Eric Kandel
    Patricia King
    Eric Parens
    Barbara Sahakian
    Paul Root Wolpe
    Nature Reviews Neuroscience, 2004, 5 : 421 - 425
  • [38] Prevention and Pharmacovigilance What Should We Do, What Can We Do?
    Edwards, I. Ralph
    DRUG SAFETY, 2012, 35 (02) : 87 - 90
  • [39] What is IOMP and for what do we need it?
    Nuesslin, Fridtjof
    ZEITSCHRIFT FUR MEDIZINISCHE PHYSIK, 2007, 17 (03): : 161 - 162
  • [40] WHAT WE CAN DO
    不详
    DEVELOPMENT-SEEDS OF CHANGE-VILLAGE THROUGH GLOBAL ORDER, 1982, (01): : 52 - 53